Clinical trials: Advanced Tumor
Breast Cancer Stage IIIA, Breast Cancer, Stage IIIB
Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast Cancer
Our study evaluates the use of Laser-Assisted Immunotherapy (LIT) plus placebo and LIT plus low-dose cyclophosphamide versus that of Standard of Care in patients presenting with Stage IIIA, IIIB or IV breast cancer.
- Conditions
- Breast Cancer Stage IIIA, Breast Cancer, Stage IIIB, Breast Cancer Stage IV
- Trial name
- NCT03202446
- Testing
- 1% Glycated Chitosan, Photothermal Laser, Cyclophosphamide
- Where
- 4 sites in Peru
- Volunteers
- 18 people
- Sponsor
- Eske Corporation S.A.C
Advanced Cancer
A Dose-Escalation Study for Patients With Advanced Cancer
This study is being conducted to determine the safety of LY2523355 for the treatment of advanced and/or metastatic cancer (including Non-Hodgkin's lymphoma).
- Trial name
- NCT01214642
- Testing
- pegfilgrastim, LY2523355
- Where
- 2 sites in United States
- Volunteers
- 63 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Renal Cell
Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma
The purpose of this study is to determine if orally-administered recombinant human lactoferrin is effective in the treatment of advanced renal cell carcinoma (RCC) in patients who have failed at least one prior systemic therapy…
- Trial name
- NCT00095186
- Testing
- Recombinant Human Lactoferrin
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Agennix
Solid Tumor, Adult, Lung Adenocarcinoma
TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor
To evaluate the safety and efficacy of T cell therapy with mutated TP53 R248Q specific TCR transduction in patients with advanced solid tumor expressing the TP53 R248Q mutation and the HLA-A*11:01 allele.
- Conditions
- Solid Tumor, Adult, Lung Adenocarcinoma, Pancreas Cancer, Colorectal Cancer
- Trial name
- NCT06619886
- Testing
- Autologous, engineered T Cells targeting TP53 R248Q
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Triple Negative Breast Cancer
Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer
This study is to compare the effective of Paclitaxel combined with Epirubicin and Paclitaxel plus Carboplatin in the neoadjuvant treatment for TNBC.
- Trial name
- NCT01276769
- Testing
- Paclitaxel plus carboplatin, Paclitaxel and epirubicin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chinese Academy of Medical Sciences
Sarcoma
Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of synovial sarcoma.
- Trial name
- NCT00052754
- Testing
- gefitinib
- Where
- 16 sites in Belgium, France and 2 more
- Volunteers
- 48 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Solid Tumor
A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
This is an open-label, multicenter, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of GDC-0994 in patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT01875705
- Testing
- GDC-0994
- Where
- 4 sites in United States, France
- Volunteers
- 40 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumors
Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors
This study evaluates the safety, tolerance, pharmacokinetics (PK), and antitumor activity of ADCT-601 in patients with advanced solid tumors.
- Trial name
- NCT03700294
- Testing
- ADCT-601
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- ADC Therapeutics S.A.
Endometrial Cancer
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy.
- Trial name
- NCT05797831
- Testing
- Navtemadlin
- Where
- 83 sites in United States, Austria and 15 more
- Volunteers
- 268 people
- Sponsor
- Kartos Therapeutics, Inc.
Neoplasms, Non-small-cell Lung Cancer
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
The purpose of this study is to learn about the: safety (the effect of the study medicine on the participant's body), effects of the study medicine alone or in combination with sasanlimab - the best amount of the study medicine.
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
- Trial name
- NCT06546553
- Testing
- PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo)
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Carcinoma, Renal Cell
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC). A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy.
- Trial name
- NCT07489495
- Testing
- Belzutifan, Zanzalintinib
- Where
- 106 sites in United States, Argentina and 17 more
- Volunteers
- 758 people
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasms
Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.
The primary objective of this trial is to determine the Maximum Tolerated Dose (MTD) of the combination of BIBW 2992/BIBF 1120 therapy administered concomitantly.
- Trial name
- NCT00998296
- Testing
- BIBW 2992, BIBF 1120
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Boehringer Ingelheim
Gastric Cancer
Real World Study of Immune Checkpoint Inhibitors for Advanced Gastric Cancer
Gastric cancer ranks as the fifth most common and the third most common cause of cancer deaths in the world. In spite of the progresses made in the diagnosis and treatment of gastric cancer in the past decades, the prognosis is…
- Trial name
- NCT04086888
- Where
- 2 sites in China
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Urothelial Carcinoma, Urothelial Carcinoma Bladder
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
This study will compare the efficacy of 9MW2821+toripalimab versus 9MW2821 monotherapy in locally advanced or metastatic urothelial carcinoma patients who have not received any systemic treatment in the metastatic or advanced…
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urothelial Carcinoma of the Renal Pelvis and Ureter
- Trial name
- NCT06823427
- Testing
- 9MW2821, Toripalimab (JS001 )
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Cancer
Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy
LVGN6051 is a humanized monoclonal antibody that specifically binds to CD137, and acts as an agonist against CD137. This first in human study of LVGN6051 is designed to establish the maximum tolerated dose (MTD) and/or the…
- Trial name
- NCT04130542
- Testing
- LVGN6051, KEYTRUDA® (pembrolizumab)
- Where
- 7 sites in United States
- Volunteers
- 105 people
- Sponsor
- Lyvgen Biopharma Holdings Limited
Pancreatic Cancer
Safety and Feasibility of imILT Locally Advanced Pancreatic Cancer (LAPC)
10 Patients with Locally Advanced Pancreatic Cancer, no further responsive to neoadjuvant treatments but with a Stage-III disease will be submitted to imILT (Immunostimulating Interstitial Laser Thermotherapy).
- Trial name
- NCT02702986
- Testing
- immunostimulating Interstitial Laser Thermotherapy, Laser
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Universita di Verona
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer and HR+/HER2- Metastatic Breast Cancer
This phase II trial studies the side effects and best dose of ivermectin in combination with balstilimab or pembrolizumab and to see how well they they work in shrinking tumors in patients with triple negative breast cancer and…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, HR+ / HER2- Advanced Breast Cancer
- Trial name
- NCT05318469
- Testing
- Ivermectin, Balstilmab, Pembrolizumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Yuan Yuan
Non-Small Cell Lung Cancer
Early Palliative Care in Patients With Advanced Lung Cancer Using an e-Health Ecosystem
Palliative care has long been associated primarily with end-of-life support. However, its scope is much broader. As highlighted in the Hastings Center Report, the purposes of medicine include not only curing disease but also…
- Trial name
- AIRPAL (NCT07039994)
- Testing
- Standard intervention, E-health intervention
- Where
- 2 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Jesús González
Melanoma
Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma
The purpose of this study is to evaluate the safety and potential effectiveness of a new treatment for advanced and recurrent melanoma involving the combination of Ipilimumab and IFN-α2b before surgery and to test for biomarker…
- Trial name
- NCT01608594
- Testing
- administration of ipilimumab10mg/kg, administration of ipilimumab 3mg/kg + HDI
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Diwakar Davar
Unspecified Adult Solid Tumor, Protocol Specific
Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth…
- Trial name
- NCT00483366
- Testing
- capecitabine, gemcitabine hydrochloride, imatinib mesylate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Nebraska
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.